1607. Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND)

BACKGROUND: CAB+RPV LA is the first complete long-acting regimen for virologically suppressed people with HIV (PWH) and demonstrated non-inferiority to standard of care antiretroviral regimens in the Phase 3/3b trials FLAIR, ATLAS, ATLAS-2M, and SOLAR. Implementation of a provider administered regim...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinclair, Gary I, Sension, Michael, Dretler, Alexandra, Schneider, Stefan, Schubert, Catherine K, Merrill, Deanna, Richardson, David, Sherif, Bintu, Zografos, Laurie, Garris, Cindy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677373/
http://dx.doi.org/10.1093/ofid/ofad500.1442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677373/
http://dx.doi.org/10.1093/ofid/ofad500.1442

Ejemplares similares